118 related articles for article (PubMed ID: 21269981)
21. [Developing a hospital-based high risk scoring model and screening strategy for pancreatic cancer].
Deng RX; Lu XH; Wang L; Li H; Qian JM; Yang AM; Zhong SX; Guo XZ; Zhou L; Wu X; Yang XO; Jiang WJ
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2038-42. PubMed ID: 16313796
[TBL] [Abstract][Full Text] [Related]
22. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
Meggiato T; Basso D; Fabris C; Fogar P; Panozzo MP; Plebani M; Faggian D; Scalon P; Ferrara C; Del Favero G
Dis Markers; 1990; 8(4):171-7. PubMed ID: 1708317
[TBL] [Abstract][Full Text] [Related]
23. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
Huang C; Bei L; Liu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
[TBL] [Abstract][Full Text] [Related]
24. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.
Gold DV; Modrak DE; Ying Z; Cardillo TM; Sharkey RM; Goldenberg DM
J Clin Oncol; 2006 Jan; 24(2):252-8. PubMed ID: 16344318
[TBL] [Abstract][Full Text] [Related]
25. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
Zhang S; Ma Y; Yang X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
[TBL] [Abstract][Full Text] [Related]
26. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
27. Receiver operating characteristic analysis: calculation for the marker 'melanoma inhibitory activity' in metastatic uveal melanoma patients.
Klingenstein A; Haritoglou I; Schaumberger MM; Nentwich MM; Hein R; Schaller UC
Melanoma Res; 2011 Aug; 21(4):352-6. PubMed ID: 21540751
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer.
Wu D; Qian JM; Deng RX; Jiang WJ; Chen YJ; Liu XH; Lu XH
Chin J Dig Dis; 2006; 7(2):117-20. PubMed ID: 16643340
[TBL] [Abstract][Full Text] [Related]
29. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
30. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
31. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach.
Fabris C; Del Favero G; Basso D; Piccoli A; Meggiato T; Angonese C; Plebani M; Leandro G; Burlina A; Naccarato R
Am J Gastroenterol; 1988 May; 83(5):549-53. PubMed ID: 3163228
[TBL] [Abstract][Full Text] [Related]
32. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
[TBL] [Abstract][Full Text] [Related]
33. CA19-9: the Italian experience.
Gullo L
Pancreas; 1994 Nov; 9(6):717-9. PubMed ID: 7846014
[TBL] [Abstract][Full Text] [Related]
34. Pancreatitis-associated protein (PAP) in patients with pancreatic cancer.
Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
Anticancer Res; 2001; 21(2B):1471-4. PubMed ID: 11396234
[TBL] [Abstract][Full Text] [Related]
35. Identification of serum biomarker signatures associated with pancreatic cancer.
Wingren C; Sandström A; Segersvärd R; Carlsson A; Andersson R; Löhr M; Borrebaeck CA
Cancer Res; 2012 May; 72(10):2481-90. PubMed ID: 22589272
[TBL] [Abstract][Full Text] [Related]
36. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
Oremek GM; Eigenbrodt E; Rädle J; Zeuzem S; Seiffert UB
Anticancer Res; 1997; 17(4B):3031-3. PubMed ID: 9329593
[TBL] [Abstract][Full Text] [Related]
37. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis value of serum B7-H3 expression in non-small cell lung cancer.
Zhang G; Xu Y; Lu X; Huang H; Zhou Y; Lu B; Zhang X
Lung Cancer; 2009 Nov; 66(2):245-9. PubMed ID: 19269710
[TBL] [Abstract][Full Text] [Related]
39. Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer.
Cai CY; Zhai LL; Wu Y; Tang ZG
Eur J Surg Oncol; 2015 Feb; 41(2):228-35. PubMed ID: 25434328
[TBL] [Abstract][Full Text] [Related]
40. [SC6 antigen for the diagnosis of pancreatic cancer before operation].
Guo XZ; Liu ZF; Ai R
Zhonghua Yi Xue Za Zhi; 1993 Jan; 73(1):26-8, 61-2. PubMed ID: 8389232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
